Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Latest RCPI Presentation: "Investor Presentation", June 2015

Highlights:

PhaseI clinical trial underway-data expected 3Q 2015

Potential Therapeutic Applications:
Autoimmune Diseases
Inflammation
Alzheimer’s Disease

Autoimmune Thyroiditis: Human Study

Preclinical Model of Multiple Sclerosis

Anatabine Citrate: Psoriasis Indication

Anatabine Citrate: Regulatory Strategy
Phase 1 underway in EU-Study Completion expected in Third Quarter/2015
Investigational New Drug Application (IND) filed with US FDA -On Clinical Hold, Company plans to respond to FDA in context of overall strategy and ongoing acquisition of preclinical and human clinical data

Initial Clinical Targets: Psoriasis & Osteoarthritis
•Dermatology (Psoriasis)
•Arthritic Conditions(Osteoarthritis)
•Inflammatory Bowel Disorders(Ulcerative Colitis, Crohn’s)
• Auto-Immune Disorders(Thyroiditis)
•CNS(Alzheimer’s, Multiple Sclerosis)

Intellectual Property-Anatabine Citrate
Novel Compound-US Patent 8,557,999
Method of Anatabine synthesis
Six pending US and foreign patents pending for “use” of Anatabine, its isomers and derivatives for inflammatory conditions

Presentation at:
http://investors.rockcreekpharmaceuticals.com/index.php?s=19&item=19